Document is current
Any future updates will be listed below
-
Authors
Scholz, Axel Tobias
Coppo, Lucia
Nolan, Edward
Hernandez, Michaella
Wang, Xuan
Mishra, Pradeep
Schnell, Robert
Pató, Zsuzsanna Anna https://orcid.org/0000-0003-2135-824X
Chen, Yifei
Dagnell, Markus
Andor, Attila https://orcid.org/0000-0002-1829-8824
Cheng, Qing
Arnér, Elias S. J.
-
Funding
Funding for this research was provided by:
Karolinska Institutet
Cancerfonden (21 1463 Pj)
Vetenskapsrådet (2021-02214)
Cayman Biomedical Research Institute
Nemzeti Kutatási Fejlesztési és Innovációs Hivatal (2022-2.1.1-NL-2022-00010, TKP2021-EGA-44 and K 146277)
Karolinska Institute
- License Information
-
More Information
Article History
Received: 13 January 2026
Revised: 26 March 2026
Accepted: 3 April 2026
First Online: 22 April 2026
Declarations
:
: Not applicable.
: ESJA and QC are shareholders and active in Selenozyme AB, a company selling recombinant selenoproteins.
